Prevent Infusion-Related Reactions With Intravenous Amivantamab: Primary Results From SKIPPirr, a Phase 2 Study
Panelists discuss managing infusion-related reactions with amivantamab and lazertinib, compare these reactions with those from other treatments, and review SKIPPirr data to provide insights on incorporating prophylactic dexamethasone 8 mg, addressing implementation barriers, and educating patients.
EP. 1: The Role of Amivantamab Plus Lazertinib for NSCLC
October 1st 2024Panelists discuss how amivantamab, FDA approved for first-line treatment of advanced non–small cell lung cancer with specific EGFR mutations, can lead to significant infusion-related reactions, including serious cases that may require dose adjustments or discontinuation.
EP. 2: Treatment-Related IRRs for Patients on Amivantamab Plus Lazertinib
October 8th 2024Panelists discuss the frequency, timing, and symptoms of infusion-related reactions with amivantamab plus lazertinib, how these drugs compare with other treatments such as datopotamab deruxtecan (DXd) or patritumab DXd (HER3-DXd), and the management strategies and prophylactic measures used, especially for patients with EGFR exon 19 or L858R advanced/metastatic non–small cell lung cancer who have experienced progression on prior therapies.
